Earnings Call Excerpt
GTx Inc (GTXI)
Q4 2008 Earnings Call
February 17, 2009; 09:00 am ET
Executives
Mitchell Steiner - Vice Chairman and Chief Executive Officer
Marc Hanover - President and Chief Operating Officer
Mark Mosteller - Chief Financial Officer
McDavid Stilwell - Director of Corporate Communications
Analysts
Eric Schmidt - Cowen & Company
Howard Liang - Leerink Swann
Joel Sendek - Lazard Capital Markets
Simos Simeonidis - Rodman & Renshaw
Aaron Reames - Wachovia Capital Markets
Presentation
Operator
Good day, ladies and gentlemen and welcome to the GTx fourth quarter and year-end 2008 conference call. My name is Ann and I’ll be your coordinator for today’s call (Operator Instructions).
I would now like to turn the presentation over to Mr. McDavid Stilwell, Director of Corporate Communications. Please Proceed.
McDavid Stilwell
On behalf of GTx, I’d like to welcome you to our fourth quarter and year-end 2008 conference call. We released our financial results earlier this morning through the newswires. If you do not have a copy of the release, you will find it on our website at www.gtxinc.com. We’ll have a replay of this call available on our website until March 3, 2009.
With me today are Dr. Mitchell Steiner, Vice Chairman and Chief Executive Officer; Marc Hanover, President and Chief Operating Officer, and Mark Mosteller, Chief Financial Officer. Following this introduction, Dr. Steiner will highlight fourth-quarter and full-year 2008 corporate developments and our plans for 2009. Next, Mr. Hanover will briefly review our financial performance. Dr. Steiner will then make some closing remarks before opening the call to questions.
Before we begin, I remind you that information discussed on this call may include forward-looking statements and such statements are subject to the risks and uncertainties we discussed in detail in our reports filed with the Securities and Exchange Commission, including in our quarterly report on Form 10-Q filed November 5, 2008. We expressly disclaim any obligation to release publicly any updates to forward-looking statements made during the call
Now I’ll turn the call over to Dr. Steiner.
Mitchell Steiner
Thank you, McDavid. 2009 will be an exciting and busy year for GTx. There are several major events that we anticipate from our four clinical development programs. As with the toremifene 80 milligrams dose to prevent fractures and treat other estrogen related side effects in men with prostate cancer and androgen deprivation therapy (ADT), we submitted the new drug application on December 30, 2008.
- To read the full transcript on Seeking Alpha, click here »
